Axogen, Inc. (AXGN)
| Market Cap | 419.81M |
| Revenue (ttm) | 127.33M |
| Net Income (ttm) | -31.80M |
| Shares Out | 41.98M |
| EPS (ttm) | -0.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 294,409 |
| Open | 9.68 |
| Previous Close | 9.52 |
| Day's Range | 9.48 - 10.06 |
| 52-Week Range | 6.87 - 22.82 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 19.38 (+93.8%) |
| Earnings Date | May 4, 2022 |
About AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM...
Financial Performance
In 2021, Axogen's revenue was $127.36 million, an increase of 13.41% compared to the previous year's $112.30 million. Losses were -$26.99 million, 13.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AXGN stock is "Buy." The 12-month stock price forecast is 19.38, which is an increase of 93.80% from the latest price.
News
Axogen Aces Phase 3 Study For Avance Nerve Graft
Axogen Inc (NASDAQ: AXGN) announced topline results from its RECON Clinical Study comparing Avance Nerve Graft to conduits in digital nerve injuries. Avance Nerve Graft is a biologically active off-the...
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of -17.65% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Axogen, Inc Reports 2022 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, toda...
Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft
RECON achieved its Primary Endpoint, a critical milestone toward transitioning Avance Nerve Graft to a licensed biologic and further supporting the expanded adoption of Avance RECON achieved its Primary...
Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
ALACHUA, Fla. and TAMPA, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
Axogen, Inc. publishes inaugural ESG Report
ALACHUA, Fla. and TAMPA, Fla., March 17, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
AxoGen (AXGN) Reports Q4 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 38.46% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Axogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla. and TAMPA, Fla., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...
Earnings Preview: AxoGen (AXGN) Q4 Earnings Expected to Decline
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen to Participate at Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...
Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...
Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings
Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for nerv...
Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation
ALACHUA, Fla. and TAMPA, Fla., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to perip...
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...
AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Axogen: Q3 Earnings Insights
Axogen (NASDAQ:AXGN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Axogen, Inc. Reports 2021 Third Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021
ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to perip...
Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand
Industry leading nerve repair surgeons will share best practices and case studies during symposium session Industry leading nerve repair surgeons will share best practices and case studies during sympos...
Axogen RECON(SM) Clinical Study Completes Subject Follow-up
RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Av...
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and 3.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Axogen, Inc. Reports 2021 Second Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, tod...
AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to per...